Want to see AMPH full AI Analyst Report?
AMPH Stock Chart & Stats
$18.72
-$0.15(-0.79%)
At close: 4:00 PM EDT
$18.72
-$0.15(-0.79%)
Day’s Range― - ―
52-Week Range$16.65 - $31.26
Previous Close$18.72
Volume445.68K
Average Volume (3M)514.01K
Market Cap
$845.70M
Enterprise Value$1.30K
Total Cash (Recent Filing)$294.39M
Total Debt (Recent Filing)$686.38M
Price to Earnings (P/E)11.8
Beta0.72
Next Earnings
Aug 06, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.71
Shares Outstanding44,092,920
10 Day Avg. Volume439,376
30 Day Avg. Volume514,011
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.59
Price to Sales (P/S)1.74
P/FCF Ratio10.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.00Price Target Upside17.52% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.58
Revenue Forecast (FY)$745.16M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent TTM operating cash flow (~$169M) and meaningful free cash flow (~$135M) provide durable internal funding for R&D, capex, share repurchases and working capital. This cash generación supports strategic flexibility through product investment and shields operations from short-term liquidity shocks.
Low Leverage / Solid Balance SheetVery low trailing leverage (debt/equity ~0.10) and sizable equity provide long-term financial flexibility to fund pipeline development, absorb regulatory remediation costs, and pursue selective M&A or licensing without pressuring liquidity or requiring dilutive financing.
Portfolio Expansion And Late-stage PipelineNew product launches like AMP-007 and confirmed late-stage biosimilar/GLP‑1 ANDA timelines create durable future revenue diversification into higher-value, complex dosage forms. Successful commercialization of these assets could sustainably shift mix toward higher-margin, less commoditized products.
Bears Say
Regulatory / GMP Warning LetterAn FDA warning letter to the subsidiary flags systemic manufacturing and quality-control weaknesses. Remediation can require capital and operational disruption, prolong compliance costs, and raise the risk of enforcement actions that could materially constrain manufacturing capacity or increase oversight over several quarters.
Earnings And Margin PressureRising cost of goods and operating expenses alongside falling adjusted and GAAP earnings indicate structural margin compression. If pricing headwinds and higher facility or SG&A costs persist, profitability and cash conversion could remain impaired for multiple quarters, limiting reinvestment capacity.
Competitive Pressure On Legacy ProductsSignificant declines in legacy product revenues reflect durable competitive and channel-rebate pressures in generics (340B, duplicate rebates, ready-to-use entrants). Continued commoditization of older assets can erode revenue stability and force margin trade-offs while relying on newer launches to replace lost cash flows.
Amphastar Pharmaceuticals News
AMPH FAQ
What was Amphastar Pharmaceuticals Inc’s price range in the past 12 months?
Amphastar Pharmaceuticals Inc lowest stock price was $16.64 and its highest was $31.26 in the past 12 months.
What is Amphastar Pharmaceuticals Inc’s market cap?
Amphastar Pharmaceuticals Inc’s market cap is $845.70M.
When is Amphastar Pharmaceuticals Inc’s upcoming earnings report date?
Amphastar Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2026 which is in 8 days.
How were Amphastar Pharmaceuticals Inc’s earnings last quarter?
Amphastar Pharmaceuticals Inc released its earnings results on May 07, 2026. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.705 by -$0.285.
Is Amphastar Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals Inc’s price is currently Undervalued.
Does Amphastar Pharmaceuticals Inc pay dividends?
Amphastar Pharmaceuticals Inc pays a Annually dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Amphastar Pharmaceuticals Inc dividends here
What is Amphastar Pharmaceuticals Inc’s EPS estimate?
Amphastar Pharmaceuticals Inc’s EPS estimate is 0.62.
How many shares outstanding does Amphastar Pharmaceuticals Inc have?
Amphastar Pharmaceuticals Inc has 44,092,920 shares outstanding.
What happened to Amphastar Pharmaceuticals Inc’s price movement after its last earnings report?
Amphastar Pharmaceuticals Inc reported an EPS of $0.42 in its last earnings report, missing expectations of $0.705. Following the earnings report the stock price went down -20.932%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amphastar Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.00 (17.52% Upside)
$22.00 (17.52% Upside)
Blogger Sentiment
Neutral
AMPH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 292.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.35%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, with operations spanning active pharmaceutical ingredient (API) manufacturing and finished-dose drug production. The company focuses on complex and technically challenging dosage forms and supplies products primarily to hospitals, clinics, and retail/wholesale pharmaceutical channels in the U.S. and select international markets.
AMPH Company Deck
AMPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operational and strategic positives (stable-to-growing total revenue, strong cash flow, successful new product launches, pipeline progress toward 2027, and active share repurchases) are offset by meaningful near-term headwinds (a 15% decline in BAQSIMI revenue driven by rebate/340B pressure, a 56% collapse in glucagon sales, rising costs and higher operating expenses, and materially lower net and adjusted earnings). Management has taken targeted actions (price increase, 340B validation, new product launch, continued R&D investment) to address the issues, but near-term margin and earnings pressure remain evident.View all AMPH earnings summariesAMPH Stock 12 Month Forecast
Average Price Target
$22.00
▲(17.52% Upside)
Technical Analysis
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
27.24% Insiders
20.96% Mutual Funds
0.75% Other Institutional Investors
27.13% Public Companies and
Individual Investors